Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide to Promote Bone Formation Before Lumbar Fusion Surgery in Postmenopausal Women With Osteoporosis
jRCTs031250119Completed
- Sponsor
- Teijin Pharma
- Start
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised trial of abaloparatide in lumbar intervertebral disc degenerative disease (LDDD) and osteoporosis (2 arms), sponsored by Teijin Pharma. Primary endpoint: Vertebral bone strength during vertebral body fusion. Started May 2025; status: completed.
02
Drugs
abaloparatide
03
Conditions
lumbar intervertebral disc degenerative disease (LDDD)osteoporosis
Beyond the preview
Go deeper on jRCTs031250119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250119.